Skip to content
Moojaz — موجز
Search
Menu
HomeRegionsMaghrebAfricaMiddle EastEuropeAsiaAmericasWorldSectionsPoliticsEconomySecurityHealthScienceTechnologyAIEnvironmentCultureSportsSearch
Switzerland · Germany · United States of America
File

Lonza–Merck: contract manufacturing divestment

This dossier follows Lonza’s planned acquisition of Merck’s CDMO business and its closing conditions.

Last updated : 1 key moments
Two test tubes.
Laboratory illustration, April 2006; not the sites involved. Jeffrey M. Vinocur, CC BY 2.5; unchanged. — Jeffrey M. Vinocur / Wikimedia Commons — CC BY 2.5 https://creativecommons.org/licenses/by/2.5/ — 21 avril 2006, sans modification.

Where things stand

Switzerland’s Lonza and Germany’s Merck KGaA announced a definitive agreement on 3 November 2026 to transfer five US pharmaceutical contract development and manufacturing sites. Closing is expected around mid-2027, subject to conditions.

Confirmed

Lonza signs deal to acquire five US sites from Merck

Switzerland’s Lonza and Germany’s Merck KGaA announced a definitive agreement on 3 November 2026 to transfer five US pharmaceutical contract development and manufacturing sites. Closing is expected around mid-2027, subject to conditions.

Two test tubes.
Laboratory illustration, April 2006; not the sites involved. Jeffrey M. Vinocur, CC BY 2.5; unchanged. — Jeffrey M. Vinocur / Wikimedia Commons — CC BY 2.5 https://creativecommons.org/licenses/by/2.5/ — 21 avril 2006, sans modification.

The transaction would increase Lonza’s US manufacturing network from four to nine sites and bring about 1,100 employees into the group. The activities include bioconjugates, viral vectors and drug-delivery technologies.

The scope includes facilities in California, Wisconsin, Missouri and Indiana. Until closing, the business remains within Merck. The announcement establishes a sale agreement, with no completed transfer of control.

Sources 3